Suppl Figure 1.pptx

1 downloads 0 Views 10MB Size Report
used to generate standard curves to determine the binding affinity of free RAD51 to each BRCn-DBD protein. B. Quantification of saturation binding analysis of.
A

RAD51 Standards

Amylose Pull-downs

RAD51

RAD51

0.1 0.2 0.4 0.8 0 0.25 0.5 1 3 6 6

BRCn-DBD Standards

BRC4-DBD 1 2

(µg)

4

BRC4-DBD RAD51 RAD51

RAD51

0.1 0.2 0.4 0.8 0 0.25 0.5 1 3 6 6

BRC1-4-DBD 1 2

(µg)

4

BRC1-4-DBD RAD51 RAD51

RAD51

0.1 0.2 0.4 0.8 0 0.25 0.5 1 3 6 6

BRC1-8-DBD 1 2

(µg)

4

BRC1-8-DBD RAD51

1 2 3 4 5 6 7 8 9 101112 13 14 SYPRO Orange

RAD51:BRCn-DBD ratio

B

8 Full-length BRCA2

6

BRC1-8-DBD BRC1-4-DBD

4

BRC4-DBD

2 0 0.0

0.5 1.0 1.5 Total RAD51 (µM)

2.0

Supplementary Figure 1

Supplementary Figure S1. Saturation binding analysis of BRCn-DBD proteins with RAD51. A. SYPRO Orange stained SDS-PAGE gels depicting RAD51 standards (lanes 1-4), amylose pull-downs (lanes 5-10), and BRCn-DBD standards (12-14). Lane 5 is BRCn-DBD alone. Lane 11 is RAD51 alone. Increasing amounts of purified RAD51 (lanes 5-10) were incubated with a fixed concentration of each BRCn-DBD protein for 30 minutes at 37 °C. The amylose beads were then washed and the protein complexes eluted with maltose. The RAD51 and BRCn-DBD standards contained known amounts of protein and were used to generate standard curves to determine the binding affinity of free RAD51 to each BRCn-DBD protein. B. Quantification of saturation binding analysis of BRCn-DBD fusions with RAD51. Increasing amounts of purified RAD51 was incubated with a fixed concentration of the indicated BRCn-DBD proteins. The data were fit to a segmental linear regression (full-length, BRC1-8-DBD, BRC1-4DBD) or a hyperbola (BRC4-DBD) using Prism 6.0. Error bars are S.D. (n=3).

A

EMSA 2XMBP - 5 10 20 40 (nM)

Protein-DNA complex Free DNA

1 2

DNA Strand Exchange

-

RAD51

B

3 4 5

2XMBP 0 2 5 10 20 40 (nM)

Product

*dsDNA 1 2

3 4 5

6 7 8

Supplementary Figure 2

Supplementary Figure S2. DNA binding and DNA strand exchange properties of purified 2XMBP tag protein alone. A. Autoradiogram of EMSA analysis depicting increasing concentrations of the purified 2XMBP tag incubated with radiolabeled 3’ tail DNA. Lane 1 is a no protein control. B. Autoradiogram of DNA strand exchange analysis using the purified 2XMBP tag protein performed as described in Fig. 3. Lane 1 is a no protein control. Lane 2 is RAD51 alone. Lanes 3-8, the reactions were pre-incubated with RPA as described in Fig. 3.

A

Biotinylated ssDNA

-/+ BRCn-DBD

Capture proteinssDNA complexes

B BRC4-DBD BRC1-4-DBD BRC5-8-DBD BRC1-8-DBD DBD kDa - 1’ 5’ 15’ 30’ 1’ 5’ 15’ 30’ 1’ 5’ 15’ 30’ 1’ 5’ 15’ 30’ 1’ 5’ 15’ 30’ 250 150

BRCn-DBD proteins 1 2

3 4

5

6

7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Anti-MBP Wash & Elute Biotinylated 167-mer BRCn-DBD Streptavidin Magnetic Bead

Supplementary Figure 3

Supplementary Figure S3. Binding analysis of BRCn-DBD proteins to biotinylated ssDNA. A. Schematic of biotinylated DNA pull-down assay. Biotinylated ssDNA was incubated with each purified BRCn-DBD or DBD protein for the indicated times, captured on magnetic streptavidin beads, washed, eluted in sample buffer, and analyzed by SDS-PAGE western blotting. B. Representative western blot to detect BRCn-DBD and DBD proteins bound and eluted from biotinylated ssDNA using an antibody directed against the MBP tag.

A

B

1 2 3 4 5 6 7

8

2XMBP-BRC1-8-DBD

Empty Vector

Empty Vector

2XMBP-Full-length BRCA2

9 10

7 21 24 25

Full-length BRCA2

BRC1-8-DBD

Anti-MBP

Anti-MBP

Surviving Fraction

1

Human BRCA2-/-

D Clone 10 Clone 9 Clone 6 Empty Vector

0.1

0.01

0.001 0.00

0.25

0.50

0.75

1.00

Surviving Fraction

C

VC8

1

0.1

Clone 7 Clone 21 Clone 24

0.01

0.001 0.00

Empty Vector

0.25

Mitomycin C (µM)

0.50

0.75

Mitomycin C (µM)

Supplementary Figure 4

1.00

Supplementary Figure S4. Analysis of single cell derived stable clones generated in human BRCA2-/- and hamster VC8 cells. A. Western blot depicting expression levels of 2XMBP tagged full-length BRCA2 in human BRCA2-/- total cell lysates from ten independent stable clones. B. Western blot depicting expression levels of 2XMBP-BRC1-8-DBD in total cell lysates from four independent VC8 stable clones. C. MMC clonogenic survival analysis of three independent human BRCA2-/- stable clones (6, 9, and 10) expressing 2XMBPfull-length BRCA2. D. MMC clonogenic survival analysis of three independent VC8 stable clones (7, 21, and 24) expressing 2XMBP-BRC1-8-DBD.

Full-length

BRC1-8-DBD

BRC5-8-DBD

BRC1-4-DBD

BRC4-DBD

DBD

N-terminus

A

C N C N C N C N C N C N C N Full-length BRCA2 BRCn-DBD proteins MBP PCNA GAPDH

B

Parental BRCA2 -/-

N-terminus

DBD

BRC1-4-DBD BRC5-8-DBD BRC1-8-DBD

Supplementary Figure 5

BRC4-DBD

Full-length BRCA2

Supplementary Figure S5. Intracellular localization of 2XMBP tagged BRCnDBD proteins in human BRCA2-/- cells. A. Biochemical fractionation of cytoplasmic (C) and nuclear (N) extracts from human BRCA2-/- cells expressing the indicated constructs. BRCn-DBD proteins were detected using an MBP antibody. PCNA and GAPDH were used to confirm biochemical partitioning of nuclear and cytoplasmic extracts respectively. B. Representative confocal images using an antibody against MBP (red) to detect intracellular localization of each stably expressed 2XMBP tagged protein in human BRCA2-/- cells. DAPI (blue) was used as a counterstain to identify the nuclei. Magnification (800X).

Human BRCA2-/-

A

Full-length

BRC5-8-DBD BRC1-8-DBD

BRC1-4-DBD

-

DBD BRC4-DBD

kDa

N-terminus

Amylose Pull-downs

BRCA2 BRCn-DBD proteins

250

MBP

RAD51 2

37

4

5

6

7

8

BRC5-8-DBD

BRC1-4-DBD

BRC4-DBD

N-terminus

-

DBD

Total Cell Lysates

B

kDa

3

Full-length

1

BRC1-8-DBD

37

RAD51

Supplementary Figure 6

Supplementary Figure S6. Endogenous RAD51 binding to BRCn-DBD proteins stably expressed in human BRCA2-/- cells. A. Cell extracts were harvested from human BRCA2-/- stable clones expressing the indicated constructs and batch bound to amylose beads in the presence of Benzonase, washed extensively, and eluted with maltose. The BRCn-DBD proteins were detected using an antibody against MBP and the endogenous RAD51 protein was detected by western blotting with an antibody against RAD51. B. Total cell lysates from the cells described in (A) were analyzed by western blotting for RAD51 expression levels.

DAPI

γ-H2AX

RAD51

Empty Vector

N-terminus

DBD

BRC4-DBD

BRC1-4-DBD

BRC5-8-DBD

BRC1-8-DBD

Full-length

Supplementary Figure 7

RAD51 γ-H2AX

Supplementary Figure S7. Ionizing radiation induced RAD51 and γ-H2AX foci in human BRCA2-/- cells expressing BRCn-DBD proteins. Representative confocal images of human BRCA2-/- cells stably expressing the indicated BRCnDBD constructs fixed and stained for RAD51 foci (green) and γ-H2AX foci (red) 8 hours following irradiation (4 Gy). Panels in far left column are DAPI (blue) stained nuclei. Boxed insets depict representative γ-H2AX and RAD51 foci used for co-localization quantification in Figure 6C. Panels in far right column are merged γ-H2AX and RAD51 foci. The images shown in each row contain the same cells.

4 Gy 8 hrs

4 Gy 48 hrs

Empty Vector RAD51

γ-H2AX

N-terminus

DBD

BRC4-DBD

BRC1-4-DBD

BRC5-8-DBD

BRC1-8-DBD

Full-length

Supplementary Figure 8

RAD51

γ-H2AX

Supplementary Figure S8. RAD51 and γ-H2AX foci in human BRCA2-/- cells expressing BRCn-DBD proteins. Representative images of RAD51 foci (green) and γ-H2AX foci (red) in human BRCA2-/- cells stably expressing the indicated BRCn-DBD constructs. Left panels are images taken 8 hours after exposure to 4 Gy of ionizing radiation. Right panels are images taken 48 hours post exposure to 4 Gy of ionizing radiation.